NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OR ANY MEMBER STATE OF THE EEA (OTHER THAN ANY MEMBER STATE OF THE EEA WHERE THE COMPANY'S SECURITIES MAY BE LEGALLY MARKETED), OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER TO ISSUE OR SELL, OR ANY SOLICITATION OF ANY OFFER TO SUBSCRIBE OR PURCHASE, ANY INVESTMENTS IN ANY JURISDICTION.
1 August 2025
HARGREAVE HALE AIM VCT PLC
(the “Company”)
Allotment of Shares
The Board announced on 9 October 2024 that the Company had published a prospectus (the “Prospectus") and had published a supplementary prospectus (the “Supplementary Prospectus”) on 20 December 2024 in relation to an offer for subscription of ordinary shares of 1 pence each (the "Ordinary Shares"), to raise up to £20,000,000 (the "Offer"). On 1 August 2025, the Company allotted 541,800 new Ordinary Shares pursuant to the Offer conditional only on Admission (the timetable for which is set out in more detail below).
The offer price at which the 541,800 new Ordinary Shares were allotted was 36.49 pence per Ordinary Share, which was calculated, in accordance with the terms of the Offer, by reference to the net asset value of an Ordinary Share on 25 July 2025 (as announced on 29 July 2025, being the last published net asset value per Ordinary Share) divided by 0.965 (to allow for the costs of the Offer).
Application will shortly be made for the 541,800 new Ordinary Shares to be admitted to the closed-ended investment funds category of the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange plc’s main market for listed securities ("Admission"). It is expected that Admission will occur and dealing will commence in the new Ordinary Shares on or around 5 August 2025. When issued, the new Ordinary Shares will rank pari passu with the existing Ordinary Shares.
As a result of the issue, the total number of Ordinary Shares in issue will be 372,927,187 with each Ordinary Share carrying one vote each. Therefore, the total voting rights in the Company will be 372,927,187. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules.
The new Ordinary Shares will be issued in registered form and may be held in uncertificated form. Definitive documents of title are expected to be dispatched within 15 business days of allotment. The new Ordinary Shares will be eligible for settlement through CREST with effect from Admission.
Unless the context requires otherwise, terms defined in the Prospectus and Supplementary Prospectus have the same meaning where used in this announcement.
END
For further information, please contact:
Canaccord Genuity Asset Management Limited
Abbe [email protected]
+44 20 7523 4525
LEI: 213800LRYA19A69SIT31
Important Information
This announcement is an advertisement for the purposes of the Prospectus Regulation Rules of the UK Financial Conduct Authority ("FCA") and is not a prospectus. This announcement does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to subscribe for or to acquire, any ordinary shares in the Company in any jurisdiction, including in or into Australia, Canada, Japan, the Republic of South Africa, the United States or any member state of the EEA (other than any member state of the EEA where the Company's securities may be lawfully marketed). Investors should not subscribe for or purchase any ordinary shares referred to in this announcement except on the basis of information in the Prospectus and the Supplementary Prospectus in their final form, published by the Company in connection with the Offer. A copy of the Prospectus and the Supplementary Prospectus are available for inspection, subject to certain access restrictions, from the Company's registered office, for viewing at the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism and on the Company's website (www.hargreaveaimvcts.co.uk). Approval of the Prospectus or the Supplementary Prospectus, by the FCA should not be understood as an endorsement of the securities that are the subject of the Prospectus. Potential investors are recommended to read the Prospectus and the Supplementary Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with a decision to invest in the Company's securities.
Issue of Equity
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...